ADAMTS13 inhibits oxidative stress and ameliorates progressive chronic kidney disease following ischaemia/reperfusion injury,Acta Physiologica

当前位置： X-MOL 学术 › Acta Physiol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

ADAMTS13 inhibits oxidative stress and ameliorates progressive chronic kidney disease following ischaemia/reperfusion injury
Acta Physiologica ( IF 5.6 ) Pub Date : 2020-11-23 , DOI: 10.1111/apha.13586
Suhan Zhou ₁ , Jie Guo ₁ , Liang Zhao _{1,

2,

3} , Yixin Liao ₄ , Qin Zhou ₁ , Yu Cui ₁ , Weipeng Hu ₁ , Jianghua Chen ₁ , Xiaoqiu Ren ₅ , Qichun Wei ₅ , Shan Jiang ₁ , Yali Zheng ₆ , Lingli Li ₇ , Christopher S Wilcox ₇ , Pontus B Persson ₂ , Andreas Patzak ₂ , Jiong Tian ₁ , En Yin Lai _{1,

2,

3}

Affiliation

Reduced A Disintegrin And Metalloproteinase with a ThromboSpondin type 1 motif member 13 (ADAMTS13) levels are observed in kidney disease. We test whether recombinant human ADAMTS13 (rhADAMTS13) mitigates renal injury in chronic kidney disease (CKD) and the potential mechanisms.

中文翻译：

ADAMTS13抑制氧化应激并改善缺血/再灌注损伤后进行性慢性肾病

在肾脏疾病中观察到具有 ThromboSpondin 1 型基序成员 13 (ADAMTS13) 水平的 A Disintegrin 和金属蛋白酶降低。我们测试重组人 ADAMTS13 (rhADAMTS13) 是否减轻慢性肾病 (CKD) 的肾损伤及其潜在机制。

更新日期：2020-11-23

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11